GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Taysha Gene Therapies
Taysha Gene Therapies is a biotech company specializing in gene therapy for rare neurological diseases. Its stock price is highly volatile and driven by news of clinical trials, as the success or failure of a single drug can determine the company's fate.
Share prices of companies in the market segment - Dna
Taysha Gene Therapies (TSHA) is a biotechnology company focused on developing gene therapies for the treatment of severe monogenic diseases of the central nervous system. We classify it as "DNA technologies." The chart below illustrates the dynamics of this cutting-edge, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
Taysha Gene Therapies is a biotech company focused on developing gene therapies for rare diseases of the central nervous system. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
TSHA - Daily change in the company's share price Taysha Gene Therapies
Shares of Taysha, a gene therapy company, are extremely volatile. Change_co measures market reactions to clinical trial data and regulatory decisions. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Taysha Gene Therapies, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TSHA, which focuses on gene therapy, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Taysha is a biopharmaceutical company specializing in gene therapy for diseases of the central nervous system. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Taysha's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Taysha Gene Therapies
Taysha is a biotech company developing gene therapy. Its shares are a bet on a breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovation market.
Annual dynamics of market capitalization of the market segment - Dna
Taysha Gene Therapies, Inc. is a biotech company developing gene therapies for rare neurological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Taysha Gene Therapies is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Taysha Gene Therapies
The value of Taysha, a gene therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its clinical trials for drugs treating rare neurological diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
Taysha Gene Therapies develops gene therapy for the treatment of severe, often rare and fatal, diseases of the central nervous system. The company's value reflects the hope that its drugs will save lives. The chart below shows the overall investor sentiment in the cutting-edge gene therapy sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Taysha Gene Therapies is a biotech company developing gene therapy for rare CNS diseases. Its shares represent a high-risk bet on the success of clinical trials. Its performance is completely disconnected from the market and is determined by scientific data and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Taysha Gene Therapies
Taysha Gene Therapies is a biotech company whose stock is driven by news. Weekly price movements reflect clinical trial data, regulatory decisions, and scientific breakthroughs. The chart clearly demonstrates the extreme volatility inherent in the gene therapy sector.
Weekly dynamics of market capitalization of the market segment - Dna
Taysha is a gene therapy company, where the stock's fortunes depend on laboratory success rather than general trends. Comparing its weekly performance with the broader biotech index only highlights its uniqueness. The chart shows how news about clinical trials causes its stock to rise or fall, completely ignoring market movements.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Taysha Gene Therapies shares exist in a reality parallel to the stock market. Their weekly performance is not a reaction to the Fed, but the result of clinical trials. A chart comparing them to the S&P 500 clearly demonstrates this disconnect: the stock can soar 100% on a day when the overall market is falling, and vice versa, confirming its binary, science-driven nature.
Market capitalization of the company, segment and market as a whole
TSHA - Market capitalization of the company Taysha Gene Therapies
Taysha Gene Therapies' market capitalization is a visualization of the enormous promise and risks in gene therapy. This clinical-stage company's chart represents not a valuation of its current business, but a bet on a future scientific breakthrough. Its sharp fluctuations are a direct reaction to trial results, FDA decisions, and funding news.
TSHA - Share of the company's market capitalization Taysha Gene Therapies within the market segment - Dna
Taysha Gene Therapies is a biotech company focused on developing gene therapies for rare diseases of the central nervous system. Its share in the sector reflects investor hopes for a breakthrough in this complex area of medicine. The chart below is a barometer of the market's faith in its scientific platform and the potential of future drugs.
Market capitalization of the market segment - Dna
Taysha Gene Therapies operates at the forefront of medicine, developing gene therapy for rare CNS diseases. The chart below shows the overall market capitalization of the DNA technology sector. Its volatility reflects the high risks and enormous potential of biotechnology, where the success of a single drug can dramatically change the valuation of the entire company.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a chart of hope and high risk in genetic medicine. Taysha is developing therapies for rare diseases of the central nervous system. Its volatile line isn't a reflection of earnings, but rather investors' bets on a scientific breakthrough. Every peak or trough represents news from the lab that could change lives and create a new market.
Book value capitalization of the company, segment and market as a whole
TSHA - Book value capitalization of the company Taysha Gene Therapies
In the case of Taysha Gene Therapies, book value represents its research reserves. The company's capital is essentially the cash raised to finance expensive gene therapy clinical trials. The chart below visualizes this "research budget," showing how it is funded and spent in the race to develop new drugs.
TSHA - Share of the company's book capitalization Taysha Gene Therapies within the market segment - Dna
Taysha Gene Therapies operates at the forefront of gene therapy, where its primary assets are not buildings but scientific discoveries. The company's physical infrastructure consists of laboratories and offices. The chart shows a minimal share of tangible assets, as its true value lies in its intellectual property and clinical trial data.
Market segment balance sheet capitalization - Dna
Gene therapy development is primarily a scientific endeavor, making Taysha relatively "lightweight." Its core value lies not in its factories, but in its intellectual property and clinical trial data. Against the backdrop of the capital-intensive pharmaceutical sector, its model is focused on R&D rather than on owning large amounts of physical assets.
Book value of all companies included in the broad market index - GURU.Markets
Taysha Gene Therapies' book value reflects the physical foundation of its cutting-edge science: state-of-the-art laboratories and equipment for gene therapy development. While its primary value lies in its intellectual property, this metric measures the tangible foundation upon which medical breakthroughs are built. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Taysha Gene Therapies
For Taysha, which has no products, book value represents its research capital. Market price represents its hope for a breakthrough in gene therapy. The ratio of these two values shows how much investors believe in its science and are willing to pay for a potential future cure. The graph is the pulse of faith in its R&D.
Market to book capitalization ratio in a market segment - Dna
Taysha Gene Therapies is a clinical-stage biotech company. It has virtually no tangible assets other than cash on hand. Its market value on this chart represents investors' pure bet on the future success of its gene therapy. This metric reflects the vast gap between its current status and the hopes for a scientific breakthrough.
Market to book capitalization ratio for the market as a whole
Taysha Gene Therapies is a biotech company at the forefront of genetic engineering. Its book value is primarily cash, but its market valuation reflects hopes for breakthroughs in treating rare diseases. This chart illustrates how significantly the valuation of such companies, dependent on faith in science and future revenue, can differ from the market average for profitable businesses.
Debts of the company, segment and market as a whole
TSHA - Company debts Taysha Gene Therapies
Taysha Gene Therapies, a clinical-stage biotech company, relies on debt and equity financing as a vital resource. Gene therapy development requires significant long-term investments in R&D and clinical trials. This chart shows how the company raises funds to advance its research and development to commercialization.
Market segment debts - Dna
Taysha is a clinical-stage biotech developing gene therapies for rare diseases. With no commercial products, its survival depends on raising capital for research. This chart illustrates the role debt plays in its survival strategy, reflecting the balance between risk and the need to fund breakthrough developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Taysha Gene Therapies
Taysha Gene Therapies is at the forefront of gene therapy, where research and clinical trials are lengthy and very expensive. This chart shows the extent to which the company relies on debt to finance its breakthrough, yet risky, developments. The trend reflects the lenders' confidence in the future success of its drugs and the company's willingness to take risks.
Market segment debt to market segment book capitalization - Dna
Taysha Gene Therapies is at the forefront of gene therapy. Research-stage biotech companies require massive capital investments with little revenue. This chart shows how the company finances its expensive research and development. It compares its debt structure to the overall biotech market cap, reflecting the high financial risk.
Debt to book value of all companies in the market
Taysha Gene Therapies operates at the forefront of genetic engineering, developing treatments for rare diseases. Biotech development is a long and capital-intensive process with unpredictable outcomes. Analyzing Taysha's debt load against the broader market, shown in the chart, helps us understand how heavily the company relies on debt to achieve scientific breakthroughs.
P/E of the company, segment and market as a whole
P/E - Taysha Gene Therapies
Taysha Gene Therapies is a biotech company developing gene therapies for rare diseases of the central nervous system. This chart reflects the high risks and expectations associated with clinical trials. The volatility of the valuation suggests that investors are reacting to every news item about trial results.
P/E of the market segment - Dna
Taysha Gene Therapies is a biotech company focused on developing gene therapies for the treatment of severe central nervous system diseases. This company is at the forefront of medical science. This chart shows the average valuation for companies in the DNA technology sector, providing investors with context for assessing Taysha's risks and potential.
P/E of the market as a whole
Taysha Gene Therapies operates at the forefront of gene therapy, where success depends on scientific breakthroughs. The valuation of such companies is rarely tied to broader market trends. Does a comparison with this chart reveal the extent to which Taysha investors are ignoring the broader economic picture, betting solely on clinical trial results and the future of medicine?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Taysha Gene Therapies
Taysha Gene Therapies is a biotech company focused on developing gene therapies for rare diseases of the central nervous system. This metric reflects investors' confidence in the future success of clinical trials. High projected values indicate expectations of a breakthrough that could transform costs into significant revenue.
%20P%2FE%20Taysha%20Gene%20Therapies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Taysha-Gene-Therapies&v=1772696716828 "Chart of the company's future (projected) P/E Taysha Gene Therapies")
Future (projected) P/E of the market segment - Dna
Taysha Gene Therapies develops gene therapy for rare diseases of the central nervous system. This is at the cutting edge of biotechnology, where the risks are enormous and the potential rewards are colossal. This chart shows average expectations for the gene therapy sector, allowing us to understand how optimistic or pessimistic the market is about Taysha compared to its competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772696716839 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Taysha Gene Therapies is a biotech company focused on gene therapy for rare neurological diseases. Its valuation is a bet on a future scientific breakthrough. This overall risk appetite chart shows how willing investors are to fund long-term, capital-intensive, and high-risk medical projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772696716839 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Taysha Gene Therapies
Taysha Gene Therapies is developing gene therapy for rare CNS diseases. The company is still in the research phase, and its revenue is minimal. The financial results in the graph do not reflect sales, but rather primarily R&D and clinical trial expenses. The profit dynamics here tell a story about the cost of innovation in biotech and the anticipation of a breakthrough.
Profit of companies in the market segment - Dna
Taysha Gene Therapies is at the forefront of the fight against rare genetic diseases of the central nervous system. For companies at the research stage, this chart is important not as a reflection of their profits, but as an indicator of the health of the entire biotech industry. The sector's high overall profitability indicates the availability of capital and the willingness of investors to fund Taysha's breakthrough projects.
Overall market profit
Taysha Gene Therapies is a biotech company developing gene therapies for rare diseases of the central nervous system. Its future depends on the success of clinical trials. The overall market situation, reflected in this chart, directly impacts its ability to raise the significant funding required to conduct complex and expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Taysha Gene Therapies
Taysha Gene Therapies is at the forefront of gene therapy, developing treatments for rare neurological diseases. The company's success depends on clinical trial results and regulatory approval. This chart shows analysts' forecasts for the potential commercialization of their developments, a key factor for a biotech startup.
%20profit%20of%20the%20company%20Taysha%20Gene%20Therapies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Taysha-Gene-Therapies&v=1772696716896 "Graph of future (projected) profit of the company Taysha Gene Therapies")
Future (predicted) profit of companies in the market segment - Dna
Taysha Gene Therapies is a biotech company operating at the forefront of gene therapy. Its success depends on clinical trial results, but investor sentiment also plays a significant role. The total revenue forecast for the gene therapy segment presented here reflects the overall level of optimism and expectations for breakthroughs, which directly impacts the valuation of such companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772696716903 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
For Taysha Gene Therapies, a development-stage biotech, this chart has an indirect significance. While its success depends on science, the overall market sentiment reflected in the forecast influences capital availability. During periods of expected growth, investors are more inclined to fund risky but promising projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772696716904 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Taysha Gene Therapies
Taysha Gene Therapies is a clinical-stage biotech company developing gene therapies for the treatment of central nervous system disorders. Since the company does not yet have stable profits, this chart is crucial. It shows how investors evaluate the potential of its scientific developments, essentially buying future revenues from the potential commercial success of its drugs.
P/S market segment - Dna
Taysha Gene Therapies is at the forefront of biotechnology, developing gene therapies for rare diseases. While the company doesn't yet have stable revenue, its valuation is based on future potential. This chart reflects the average valuation in the sector, providing insight into how investor expectations for Taysha's science compare to industry sentiment.
P/S of the market as a whole
Taysha Gene Therapies is a cutting-edge gene therapy biotechnology company developing treatments for rare neurological diseases. Its value reflects expectations of future breakthroughs. This metric, reflecting market revenue estimates, serves as a benchmark for Taysha. It demonstrates how much investors are willing to pay upfront for scientific potential compared to companies in the real sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Taysha Gene Therapies
Taysha Gene Therapies is a biotech company working at the forefront of gene therapy for rare CNS diseases. Companies like these may have zero revenue today, and their valuation is based solely on their belief in future success. This metric reflects investors' hopes for drug approval and subsequent multibillion-dollar sales.
%20P%2FS%20Taysha%20Gene%20Therapies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Taysha-Gene-Therapies&v=1772696716915 "The graph of the company's future (projected) P/S Taysha Gene Therapies")
Future (projected) P/S of the market segment - Dna
Taysha Gene Therapies is a biotech company focused on developing gene therapies for the treatment of rare diseases of the central nervous system. For such companies, valuation depends on future success. This chart displays industry-average revenue expectations, allowing investors to compare Taysha's market outlook with other players in the innovative pharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772696716943 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Taysha Gene Therapies is at the forefront of genetic engineering, developing treatments for rare diseases of the central nervous system. The optimism expressed in this chart is largely fueled by expectations for such biotechnological breakthroughs. Each successful stage of Taysha's clinical trials not only brings hope to patients but also signals to the market the potential of the entire industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772696716955 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Taysha Gene Therapies
This chart shows the financial results of Taysha Gene Therapies, a biotech company focused on developing gene therapies for rare diseases of the central nervous system. As a research-stage company, its revenue is often tied to licensing agreements and partnerships. The trend reflects progress in commercializing its research findings.
Sales of companies in the market segment - Dna
Taysha Gene Therapies is a clinical-stage biotechnology company developing gene therapies for rare CNS diseases. This chart shows the total revenue in the sector. Although Taysha does not yet generate stable revenue, its research and potential future success could dramatically impact the size of this market by turning scientific breakthroughs into commercial products.
Overall market sales
Taysha Gene Therapies is a research-stage biotech company whose funding depends on investor risk appetite. This pattern of overall economic activity indirectly influences market sentiment. During periods of growth, investors are more willing to invest in long-term, risky projects like Taysha's.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Taysha Gene Therapies
Taysha is a biotech company developing gene therapies. Because its products are still in development, this chart reflects potential future revenue rather than current revenue. It illustrates analysts' confidence in the success of clinical trials and the commercial potential of its innovative drugs.
%20sales%20of%20the%20company%20Taysha%20Gene%20Therapies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Taysha-Gene-Therapies&v=1772696716983 "Schedule of future (projected) sales of the company Taysha Gene Therapies")
Future (projected) sales of companies in the market segment - Dna
Taysha Gene Therapies operates at the forefront of medicine, developing gene therapies for the treatment of rare and severe diseases of the central nervous system. The company's future depends entirely on the success of clinical trials and subsequent commercialization. This forecast reflects the enormous potential and risks of the entire gene therapy market, in which Taysha seeks to carve out its niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772696716984 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Taysha Gene Therapies operates in the gene therapy field, where funding and development cycles depend on the overall investment climate. This chart illustrates economic expectations, which influence investor willingness to invest in long-term and risky biotech projects. Taysha's success depends on the availability of capital, which is closely tied to market forecasts.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772696716985 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Taysha Gene Therapies
For Taysha Gene Therapies, a clinical-stage biopharmaceutical company, traditional profitability is not yet feasible. The graph below reflects its operating losses—the result of massive investments in gene therapy research and development. This is the price the company is paying for a potential breakthrough in the treatment of rare diseases.
Market segment marginality - Dna
#VALUE!
Market marginality as a whole
Taysha Gene Therapies is developing gene therapy for rare diseases of the central nervous system. This is cutting-edge science, requiring significant investment. This graph shows the overall profitability of the economy, which indirectly impacts Taysha. High market profitability creates a favorable climate for funding risky but potentially breakthrough biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Taysha Gene Therapies
Taysha Gene Therapies is a clinical-stage biotechnology company developing gene therapies. Its team is its greatest asset, consisting primarily of scientists and clinical development specialists. The growth seen in this graph directly correlates with the progress of its research programs and the transition to larger trials.
Share of the company's employees Taysha Gene Therapies within the market segment - Dna
Taysha Gene Therapies is at the forefront of medicine, developing gene-based treatments for rare diseases of the central nervous system. The graph below measures the company's industry weight through its human resources. In biotech, where every employee is a scientist or clinician, increasing this share means increasing scientific capacity to conduct complex research and save lives.
Number of employees in the market segment - Dna
Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for the treatment of monogenic CNS diseases. This chart shows employment trends in the highly specialized field of genetic engineering. The growing number of researchers and clinicians in this field reflects not only the company's progress but also the overall scientific breakthrough in the fight against rare genetic diseases.
Number of employees in the market as a whole
Taysha Gene Therapies develops treatments for rare genetic diseases of the central nervous system. The company is at the forefront of biotech innovation, where success depends on scientific breakthroughs. This metric demonstrates how investments in complex biotech are impacting the labor market, increasing demand for highly specialized scientists and researchers.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Taysha Gene Therapies (TSHA)
Taysha Gene Therapies is a clinical-stage biotech company. This chart doesn't reflect current performance, as the company doesn't yet have commercial products. It shows how highly the market values its intellectual capital—the potential of its gene therapies. This is the net value of its patent portfolio and research per scientist and employee.
%20of%20the%20company%20Taysha%20Gene%20Therapies%20(TSHA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Taysha-Gene-Therapies-TSHA&v=1772696717044 "Chart of market capitalization per employee (in thousands of dollars) of the company Taysha Gene Therapies (TSHA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Taysha Gene Therapies is a biotechnology company focused on developing gene therapies. Its market capitalization is based on the potential for future discovery and commercialization of drugs, rather than current revenue. This metric demonstrates a high assessment of the company's intellectual capital and future prospects, distributed among a small team of highly qualified scientists.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772696717046 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Taysha Gene Therapies is a biotech company specializing in gene therapy for rare neurological diseases. This chart reflects the valuation of a cutting-edge scientific platform. The company's entire value is derived from its intellectual property and life-saving potential. This metric demonstrates the enormous value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772696717058 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Taysha Gene Therapies (TSHA)
Taysha Gene Therapies is a cutting-edge biotech company developing gene therapy for severe CNS diseases. This is pure R&D. This chart isn't about profit; it shows the "cost of hope"—the amount of investment (research, clinical trials) required for each highly qualified scientist working on a potential blockbuster.
%20Chart%20Taysha%20Gene%20Therapies%20(TSHA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Taysha-Gene-Therapies-TSHA&v=1772696717059 "Company Profit Per Employee (in thousands of dollars) Chart Taysha Gene Therapies (TSHA)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Taysha Gene Therapies is a clinical-stage biotech company developing gene therapies for rare neurological diseases. During the R&D phase, this metric is always negative (loss per employee). This graph doesn't show profit, but rather the rate of capital burn per scientist in the process of creating breakthrough drugs.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772696717067 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Taysha Gene Therapies is a clinical-stage biotechnology company specializing in gene therapy for rare neurological diseases. The company has no commercial products and, therefore, no profit. This chart shows the operating loss per employee (scientist, administrator). It reflects the "burn rate" of capital spent on breakthrough R&D.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772696717068 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Taysha Gene Therapies (TSHA)
Taysha Gene Therapies is developing gene therapy for rare CNS diseases. This graph is an indicator of the commercial potential of its research. Since the company is in the research phase, any increase in revenue per employee is likely due to partnerships or licensing, rather than sales of the finished product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Taysha-Gene-Therapies-TSHA&v=1772696717070 "Sales chart per company employee Taysha Gene Therapies (TSHA)")
Sales per employee in the market segment - Dna
Taysha Gene Therapies is a cutting-edge genetic engineering company where scientific capital is king. This chart helps you evaluate how effectively Taysha's team, comprised of highly skilled scientists and researchers, converts its research into revenue (e.g., through partnerships or early sales) compared to other gene therapy companies.
Sales per employee for the market as a whole
Taysha (TSHA) is working on cutting-edge gene therapy, developing drugs for monogenic CNS diseases. Like many biotech companies in the pre-revenue stage, the company does not yet have a commercial product. This statistic illustrates a classic situation for an R&D company: a significant staff of highly qualified scientists working at a loss while creating future intellectual property.
Short shares by company, segment and market as a whole
Shares shorted by company Taysha Gene Therapies (TSHA)
Taysha Gene Therapies is a biotech company developing gene therapy for CNS disorders. It's a binary field: either resounding success or failure. This chart shows how many investors don't believe in the success of its clinical trials and are betting that its cutting-edge developments won't prove effective or safe.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Taysha-Gene-Therapies-TSHA&v=1772696717084 "Short Shares Chart for the Company Taysha Gene Therapies (TSHA)")
Shares shorted by market segment - Dna
Taysha Gene Therapies is a biotech company developing gene therapy for severe neurological diseases (such as Rett syndrome). This indicator represents a short bet. "Shorts" here are a direct bet that their risky clinical trials will fail or that their technology will not be approved by the FDA.
Shares shorted by the overall market
Taysha Gene Therapies (TSHA) is a biotech company focused on gene therapy for rare neurological diseases. These are risky but potentially breakthrough developments. This chart shows bets against their leading programs. Bears may doubt the safety or efficacy of their drugs or believe that manufacturing challenges will make their therapies unviable.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Taysha Gene Therapies (TSHA)
Taysha Gene Therapies is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Taysha-Gene-Therapies-TSHA&v=1772696717101 "RSI 14 indicator chart for the company's stock Taysha Gene Therapies (TSHA)")
RSI 14 Market Segment - Dna
Taysha (TSHA) is a biotech company focused on gene therapy (AAV) for the treatment of severe neurological diseases (Rett syndrome). The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is TSHA's volatility a reaction to their trials or is the entire sector overheated?
RSI 14 for the overall market
Taysha Gene Therapies (TSHA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TSHA (Taysha Gene Therapies)
Taysha Gene Therapies (TSHA) is a biotech company developing gene therapies for rare neurological diseases. This chart shows the average price target, reflecting analysts' opinions on the potential of their developments and critical clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TSHA-Taysha-Gene-Therapies&v=1772696717138 "A chart showing analyst consensus forecasts for the expected stock price. TSHA (Taysha Gene Therapies)")
The difference between the consensus estimate and the actual stock price TSHA (Taysha Gene Therapies)
Taysha Gene Therapies is a biotech company focused on developing gene therapies for the treatment of severe monogenic CNS diseases. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the success of clinical trials and the company's platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TSHA-Taysha-Gene-Therapies&v=1772696717144 "A chart showing the difference between the consensus forecast and the actual stock price. TSHA (Taysha Gene Therapies)")
Analyst consensus forecast for stock prices by market segment - Dna
Taysha Gene Therapies is a biotech company developing gene therapies for rare and severe neurological diseases (such as Rett syndrome). This chart shows analysts' overall expectations for the entire DNA technology sector. It reflects how confident experts are in the success of this complex R&D platform.
Analysts' consensus forecast for the overall market share price
Taysha Gene Therapies is a biotech company specializing in gene therapy for rare neurological diseases, primarily in children. This is breakthrough but complex science. This chart shows overall market sentiment. For Taysha, as an R&D company, it's important to understand how the overall risk appetite (sentiment) influences the funding of their expensive and risky programs. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Taysha Gene Therapies
Taysha (TSHA) is a clinical-stage biotech focused on gene therapy for rare and severe CNS (central nervous system) diseases. This chart represents a high-risk R&D bet. Its valuation reflects the binary belief of investors in their scientific platform (AAV vectors) and their clinical trial data.
AKIMA Market Segment Index - Dna
Taysha (TSHA) is a clinical-stage biotech focused on CNS gene therapy; the company is developing (AAV) drugs for the treatment of rare, fatal neurological diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (but risky) R&D platform (TSHA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Taysha Gene Therapies is a biotech company focused on monogenic CNS diseases. It is a leader in developing gene therapy for Rett syndrome. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific play targeting rare diseases compares to overall economic trends.
